Currently, there are 80.10M common shares owned by the public and among those 78.64M shares have been available to trade.
The company’s stock has a 5-day price change of 121.60% and 169.55% over the past three months. CTMX shares are trading 106.80% year to date (YTD), with the 12-month market performance down to -49.16% lower. It has a 12-month low price of $0.40 and touched a high of $2.05 over the same period. CTMX has an average intraday trading volume of 2.34 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 151.85%, 205.64%, and 118.72% respectively.
Institutional ownership of CytomX Therapeutics Inc (NASDAQ: CTMX) shares accounts for 58.10% of the company’s 80.10M shares outstanding.
It has a market capitalization of $171.72M and a beta (3y monthly) value of 1.16. The stock’s trailing 12-month PE ratio is 5.42, while the earnings-per-share (ttm) stands at $0.39. Price movements for the stock have been influenced by the stock’s volatility, which stands at 24.03% over the week and 14.59% over the month.
Earnings per share for the fiscal year are expected to decrease by -74.47%, and -648.43% over the next financial year.
Looking at the support for the CTMX, a number of firms have released research notes about the stock. Piper Sandler stated their Overweight rating for the stock in a research note on April 14, 2025, with the firm’s price target at $3.25-$2.50. Piper Sandler coverage for the CytomX Therapeutics Inc (CTMX) stock in a research note released on May 28, 2024 offered a Overweight rating with a price target of $3.50. Wedbush was of a view on May 09, 2024 that the stock is Outperform, while Jefferies gave the stock Buy rating on May 06, 2024, issuing a price target of $2.50- $8. JP Morgan on their part issued Neutral rating on April 22, 2024.
